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Key Messages
l	 Two-thirds of participants (66%) completed their index abstinence-based 
treatment programme; 27% dropped out before programme completion. 
l	 Only 11% of individuals recruited within the abstinence modality were 
female. 
l	 Abstinence from all drugs (including prescribed methadone and 
excluding alcohol) increased from 18% at treatment intake to 41%  
at 1-year. 
l	 Cannabis was the only target drug where no reductions in the numbers 
reporting use at treatment intake and 1-year were observed. 
l	 The most substantial reductions over the follow-up period was in 
participants’ cocaine use, in terms of the proportions reporting use, the 
frequency of use and quantities consumed.
l	 Levels of involvement in crime reduced across six of the 12 categories  
of offences.
l	 Improvements were observed in nine of the 10 physical health 
symptoms, and five of the 10 mental health symptoms.
l	 The mortality rate of the cohort was 1.2% (1/82).
l	 Increases in contact with two health and social care services  
(GPs and employment/educations agencies) were reported.
abstinence Modality
For the purpose of this study the abstinence modality is defined as being 
any structured programme which required individuals to be drug-free 
(including free from any pharmacological intervention) in order to participate 
in, and remain on, the programme. Such programmes provide intensive 
psychological support and a structured programme of daily activities which 
participants are required to attend. Treatment can occur in an inpatient 
(often referred to as residential rehabilitation) or an outpatient (i.e. 
structured drug-free day programmes) setting.
Inpatient abstinence-based treatment programmes can differ markedly in 
their underlying philosophy, programme structure, intensity and duration. 
Programmes may be either short-term (usually between 4-12 weeks) or 
long-term (usually between 3-12 months). ROSIE study participants were 
recruited from the three main types of residential rehabilitation programmes 
identified in the international literature; 12-step/Minnesota Model 
programmes, Christian houses, and a therapeutic community.
In summary, 85% (n=70) of the ROSIE abstinence cohort were recruited 
from inpatient and 15% (n=12) from outpatient settings.
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Research Outcome study in Ireland 
(ROsIE)
The Research Outcome Study in Ireland (ROSIE) is the 
first national, prospective, longitudinal, multi-site drug 
treatment outcome study in the country. The National 
Advisory Committee on Drugs (NACD) commissioned 
this research in 2002 as required by the National 
Drugs Strategy Action 99. The aim of the Study is to 
recruit and follow opiate users entering treatment over 
a period of time documenting the changes observed. 
The contract was awarded to Dr Catherine Comiskey 
and NUI Maynooth. 
The ROSIE study follows participants from the point 
of commencing a new treatment episode (treatment 
intake) and monitors progress at time-anchored points; 
6 months, 1-year and 3-years after treatment intake. 
Between September 2003 and July 2004, the ROSIE 
study recruited 404 opiate users on entry into three-
index treatments; methadone maintenance/reduction 
(53.2%, n=215) structured detoxification (20%, 
n=81) and abstinence-based treatment (20.3%, 
n=82). In addition, a sub-sample of opiate users were 
recruited from needle-exchanges (6.4%, n=26).These 
modalities were part of the tender brief from the 
NACD as they were considered to represent the most 
widely implemented interventions for opiate users in 
Ireland. 
abstinence cohort: Follow-up rates
Of the 82 people recruited within the abstinence 
modality, 98% (n=80) were located, and 68% 
(n=56) successfully completed a 1-year interview. One 
individual died within the follow-up period, two people 
withdrew from the study, 21 people were located but 
not successfully interviewed, and an additional two 
participants were not located. These 26 people ‘lost’ to 
follow-up were excluded from the comparative analysis 
to allow for valid assessment across the two time 
periods. This is the third paper in the ROSIE Findings 
series and it provides a snapshot of the outcomes 
for people in the abstinence modality one year after 
treatment intake.
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MeTHODOLOgy
1. study design
The 404 ROSIE study participants were recruited from both inpatient (hospital, residential programmes & prisons) and outpatient settings 
(community-based clinics, health board clinics & GPs). Participants had to be over 18 years, commencing a new treatment episode, 
prepared to consent to the tracking/follow-up procedures, and willing to provide locator information. Treatment agencies participating in 
the study were purposively (not randomly) sampled to reflect drug treatment in Ireland, and the known geographical spread of provision 
and range of services. In total, 44 agencies providing approximately 54 services located in rural, urban and inner-city areas of Ireland were 
involved in the study. In addition, a Research Advisory Group was established by the NACD to support and monitor the research project. 
Participants were interviewed at the three time periods using a pre-prepared interview schedule which examined key outcome measures 
including
l	 Drug use (drug type, frequency, cost and quantity of drug use)
l	 General health (a 10-point physical & mental health assessment)
l	 Social functioning (employment, accommodation, involvement in crime)
l	 Harm (injecting behaviour & experience of overdose)
l	 Mortality (participant/contact feedback & checking non-followed-up participants against the General Mortality Register).
In addition to a lifetime measure, measures were taken of behaviours in the 90 days preceding interviews, except for injecting-related risk 
behaviour variables when 30 days was used. Individuals were asked about their use of 16 substances. This document focuses on the 
seven most frequently reported problem drugs – referred to as target drugs – (i.e. heroin, methadone (non-prescribed), benzodiazepines 
(non-prescribed), cocaine powder, crack cocaine, cannabis & alcohol) and reports changes in use patterns at 1-year. 
2. Follow-up
Follow-up of participants was assisted by the provision of at least four contacts (locator information) for each person (including a drug 
treatment contact, family member, GP & others). A small remuneration was provided at 1-year follow-up to acknowledge the ongoing 
participation of the individual in the study. 
3. study limitations
1. Although the findings presented here highlight positive outcomes for study participants, they do not indicate a direct causal 
relationship between the treatment received and the outcomes observed.
2. The study did not randomly allocate participants to treatment settings/modality or employ a control group (drug users with similar 
profiles not attending the index treatment).
3. Any individual behaviour change is the result of the interaction of three factors, the person, the environment and the intervention, all of 
which can influence outcomes but could not be controlled for in this study. 
4. Understanding this paper
Data are presented on the 56 individuals recruited within the abstinence modality who completed treatment intake and 1-year follow-up 
interviews. Only individuals who provided valid answers to each individual question at the two time periods were included in the analysis. 
Missing data were handled by excluding the cases from the particular analysis. Changes in categorical variables were analysed using the 
McNemar test. When the results of these tests were found to be statistically significant1 an asterisk (*) was inserted into the frequency 
tables and/or graphs. Full details of these tests will form part of the ROSIE Study Technical Report on 12-month Outcomes. Percentages 
are rounded up. Comparisons of means were analysed using paired-sample t-tests (‡ indicates statistical significance). 
5. ROsIE Findings series
• ROsIE Findings 1 reported on the 1-year outcomes for the followed-up population (n=305) across all modalities.
• ROsIE Findings 2 presented 1-year outcomes for individuals recruited within the detoxification modality. 
• ROsIE Findings 3 (this document) reports 1-year outcomes for individuals recruited within the abstinence modality. 
• ROsIE Findings 4 (forthcoming) will present 1-year outcomes for individuals recruited within the methadone modality.
Further issue-based papers will be published in due course.
1  Statistical significance can only be stated when tests have been carried out on the data to establish the degree of confidence with which we can 
infer that the differences in the observed findings are true and not due to sampling or other error. This is usually reported at a 5% level of probability 
which means where a p value is found to be less then or equal to 0.05 we can be confident that 95 times out of 100 the outcomes and differences 
observed are not due to chance.
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Profile of Participants at  
Treatment Intake
The demographic characteristics of participants (n=82) in the 
abstinence modality are presented in Table 1. The treatment 
entrants were typically male, on average 27 years-of-age and 
primarily reliant on social welfare payments. Less than half the 
cohort were parents of children under 18 years-of-age, most 
of whom (77%) did not have their children in their care. The 
majority of entrants had spent some time in prison (72%), and 
16% were homeless in the 90 days prior to treatment intake 
interview. 
Table 1 Demographic profile of participants
Gender (% male) 89
Average age (yrs) 27
a Early school leavers (%) 30
b Main source of income (%)
  Social welfare 70
  Employed 30
b Homeless (%) 16
Ever in prison (%) 72
Parents (%) 47
a Defined as leaving school before 16 years, or before completion of 
three years of post-primary education (Education, Welfare Act 2000)
b In the 90 days prior to intake interview
Treatment Completion Rates
Figure 1 shows that the treatment completion rate was high; 
the majority of participants (66%) successfully completed their 
index treatment. Over one-quarter of the cohort dropped out of 
treatment (27%) and 2% of participants transferred to another 
treatment type before completing the index abstinence-based 
treatment programme. Finally three individuals (5%) were still in 
their index treatment at 1-year.














Treatment status at 1-year
One year after treatment intake, 64% (n=36) of participants 
reported being in some form of drug treatment. Less then one-
quarter of the cohort were on a methadone programme (23%). 
No participants were in a structured detoxification programme 
and 5% (n=3) were in a (their index) residential rehabilitation 
abstinence-based treatment programme. Twenty-three per cent 
of the cohort attended one-to-one counselling and 37% were 
in group work - this category includes Narcotic Anonymous (NA) 
meetings, aftercare, programmes and structured day programmes.
Table 2 Treatment category at 1-year interview
a Treatment at 1-year % n
Currently in Treatment 64 36
Methadone maintenance/reduction 23 13
Detoxification programme 0 0
Residential rehabilitation 5 3
One-to-one counselling 23 13
Group Work 37 21
a Percentages do not sum to 100, as categories are not mutually 
exclusive
Drug Use Outcomes
The number of people who reported using heroin, methadone 
(non-prescribed), benzodiazepines (non-prescribed), cocaine 
powder, crack cocaine and alcohol in the 90 days prior to 
interview decreased between treatment intake and 1-year 
follow-up (see Table 3). Polydrug use in the 90 days prior to 
interview also reduced; from 66% (n=37) at treatment intake 
to 41% (n=23) at 1-year. The average number of days in which 
methadone (non-prescribed), benzodiazepines (non-prescribed), 
and cocaine were used in the 90 days prior to interview reduced 
and non-significant reductions were observed in the frequency 
of use of the remaining substances. In addition, non-significant 
reductions were observed in the proportions who reported 
cannabis and in the frequency of its use. The consumption levels 
of heroin, methadone (non-prescribed), cocaine and cannabis 
reduced over the time period, as indicated by changes in the 
mean daily quantity used in the 90 days prior to interview.
The most substantial reduction over the follow-up period was in 
cocaine use, in terms of the proportions of participants using the 
drug (46% at treatment intake compared with 14% at 1-year), 
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Table 3 Drug use in the 90 days prior to treatment intake & 1-year interview
% Used Mean days used Mean daily quantity used
Intake 1-year Intake 1-year Intake 1-year
% n % n Mean sd Mean sd Mean sd Mean sd
Heroin (grams) 65 34 42 22* 27.4 32.1 16.6 29.3 0.8 1.0 0.3 1.0 ‡
a Methadone (mls) 36 20 13 7* 9.2 21.3 2.8 12.8 ‡ 14.9 29.6 5.2 14.9 ‡
a Benzodiazepines 
(mgs)
37 20 15 8* 10.6 20.4 1.4 5.3 ‡ 48.1 171.4 5.7 23.1 
Cocaine (grams) 46 26 14 8* 9.9 18.5 2.0 7.9 ‡ 1.0 1.7 0.3 0.9 ‡
Crack cocaine 21 12 5 3* 3.5 13.6 0.7 4.1 nc nc nc nc
Cannabis (joints) 54 26 40 19 31.9 35.4 22.2 35.4 13.7 28.0 2.8 6.2 ‡
Alcohol (units) 60 30 36 18* 17.9 28.8 10.4 23.4 14.1 20.8 8.2 26.4 
* McNemar test revealed statistically significant changes. ‡ Paired t-test showed statistical significance. nc (not calculated) Crack cocaine was excluded from  
the analysis due to the inconsistency in the way data was reported. a Refers to the use of non-prescribed drugs.
Drug abstinence Rates
At treatment intake 18% (n=9) of participants reported that they 
had not used any drugs (excluding alcohol and/or prescribed drugs) 
in the preceding 90 days. By 1-year interview this had increased to 
41% (n=21) of participants (See Figure 2). Similarly, abstinence 
from all drugs excluding alcohol, including prescribed drugs such as 
methadone was also 18% at treatment intake vs. 41% at 1-year. 
Figure 2 Illicit drug abstinence rates in 90 days prior to 
















average amount spent on each drug
The aforementioned changes in reported drug use were accompanied 
by the following changes in the average amount individuals spent (€) 
on a typical drug using day, on four substances: 
l	 A reduction in the average daily heroin spenda from €114.60 at 
treatment intake (sd=149.0) to €47.50 at 1-year (sd=177.50)
l	 A reduction in the average daily cocaine powder spendb from 
€109.20 at treatment intake (sd=190.90) to €18.20 at 1-year 
(sd=61.60) 
l	 A non-significant reduction in the average daily crack cocaine 
spendc from €62.40 at treatment intake (sd=244.40) to €9.00 at 
1-year (sd=50.90)
l	 A reduction in the average daily cannabis spendd from €5.40 at 
treatment intake (sd=10.80) to €1.00 at 1-year (sd=2.20). 
a Based on a bag of heroin (0.113 grams) costing €20
b Based on 1 gram of cocaine powder costing €110 at intake €66 at 1-year
c Based on 1 rock costing €50 and/or the cost of cocaine powder as above
d Based on 1 ounce of cannabis costing €110 at intake €100 at 1-year 
(cost per joint, 39c at intake 35c at 1-year)
Crime Outcomes
There was a reduction in the percentage of participants involved in 
acquisitive crime, from 35% (n=19) at treatment intake to 13% 
(n=7) at 1-year. 
The numbers of participants involved in the selling/supplying of drugs 
in the 90 days prior to interview decreased between treatment intake 
and 1-year (see Table 4). In addition, the proportion of participants 
who committed theft from a person, theft from a house/home, 
handling stolen goods, fraud/forgery/deception and assault also 
reduced over this time period.
Overall, a higher proportion of participants reported no criminal 
involvement in the 90 days prior to interview at 1-year (76%) 
compared to treatment intake (43%).
Table 4 Offending behaviour in the 90 days prior 
to treatment intake & 1-year interview
% committed
Intake 1-year
% n % n
Selling/supplying 35 19 9 5*
Theft from a person 19 10 4 2*
Theft from a house/
home
13 7 0 0*
Theft from a shop etc. 17 9 9 5
Theft from a vehicle 8 4 0 0
Theft of a vehicle 7 4 0 0
Handling stolen goods 31 17 9 5*
Fraud/forgery/
deception
19 10 2 1*
Assault 16 9 2 1*
Criminal damage 11 6 2 1
Soliciting 0 0 0 0
Breach of the peace 6 3 4 2
* McNemar test revealed statistically significant changes
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Risk Behaviour Outcomes
The reduction in participants’ drug use was accompanied by a 
non-significant decrease in the numbers who reported injecting 
drug use. At treatment intake 30% (n=17) of the cohort injected 
a drug in the 90 days prior to interview compared with 20% 
(n=11) at 1-year. However a reduction in the proportions 
injecting one of the three most commonly injected substances, 
benzodiazepines, was observed; from 11% (n=6) at treatment 
intake to zero per cent at 1-year (see Figure 3).
Although there was no significant decrease in the frequency 
of injecting drug use (an average of 12.4 days out of 90 at 
treatment intake (sd=25.6) compared with 9.7 days (sd=24.9) 
at 1-year) reductions in the average times per day participants 
injected in the 90 days prior to treatment intake and 1-year 
interview were observed. At treatment intake participants reported 
injecting on average 1.3 times per days (sd=2.6) compared with 
an average of 0.4 times per day (sd=1.0) at 1-year. 
The proportion of participants who reported an overdose in the 
previous 90 days remained the same over the two time periods 
at 4% (n=2). 
Figure 3 Injecting drug use by drug type in the 90 




















* McNemar test revealed statistically significant change
 
There were no changes in participants’ injecting-related risk 
behaviours. At treatment intake participants reported low rates of 
borrowing, lending, reusing own injecting equipment, and sharing 
of injecting paraphernalia (e.g. spoons and filters). With the 
exception of a decrease in the numbers who reported borrowing, 
these behaviours remained the same over time (see Table 5).
Table 5 Injecting-related risk behaviour in the 30 
days prior to treatment intake & 1-year interview
% reported
Intake 1-year
% n % n
Borrowed used needles/
syringes
8 4 2 1
Lent used needles/syringes 2 1 2 1
Reused own needles/
syringes
9 4 9 4
Used filters/spoons after 
someone
0 0 0 0
Health Outcomes
Improvements in both the physical and mental health symptoms 
of the cohort were evident over the relatively short time period. 
The numbers of participants who reported nine of the 10 
physical health symptoms reduced from treatment intake to 1-
year (see Table 6). A non-significant reduction was observed in 
the numbers who reported the remaining health symptom (chest 
pains).
Some of the most marked reductions were observed in the 
symptoms associated with opiate withdrawals (such as tremors/
shakes, joint/bone pains, and muscle/pains).
Table 6 Physical health symptoms in the 90 days 
prior to treatment intake & 1-year interview
% reported
Intake 1-year
% n % n
Poor appetite 63 31 41 20*
Tiredness/fatigue 82 41 40 20*
Nausea (feeling sick) 49 24 18 9*
Stomach pains 42 21 14 7*
Difficulty breathing 35 17 17 8*
Chest pains 22 11 16 8
Joint/bone pains 57 28 14 7*
Muscle pains 50 25 12 6*
Numbness/tingling 
arms/legs
26 13 8 4*
Tremors/shakes 51 25 6 3*
* McNemar test revealed statistically significant changes
Table 7 illustrates that there were reductions in the number 
of participants who reported suffering from five of the 10 
mental health symptoms. Most of these reductions were in 
anxiety related symptoms (i.e. feeling tense, suddenly scared 
for no reason, nervous/shaking inside and feeling fearful). 
Although there were reductions in the numbers who reported 
the remaining, largely depressive-type symptoms (i.e. feeling 
hopeless about the future, feelings of worthlessness, and no 
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Table 7 Mental health symptoms in the 90 days 
prior to treatment intake & 1-year interview
% reported
Intake 1-year
% n % n
Feeling tense 88 37 40 17*
Suddenly scared for no 
reason
47 20 16 7*
Feeling fearful 76 29 29 11*
Nervous/shaking inside 59 24 29 12*
Panic attacks 24 11 22 10
Feeling hopeless about 
future
55 24 43 19
Feelings of 
worthlessness
62 26 40 17
No interest in things 65 28 47 20
Feeling lonely 76 32 55 23*
Thoughts of ending life 26 12 17 8
* McNemar test revealed statistically significant changes
service Contact
There was an increase in participants’ contact with two social 
care services (GPs and employment/education services) from 
treatment intake to 1-year (see Table 8). In addition, although not 
statistically significant, participants reported increased contact with 
housing/homeless services, social welfare services, and hospitals.
Table 8 Contact with health & social care services 




% n % n
Stayed overnight in 
hospital
7 4 9 5
Treated in A & E 9 5 13 7
Seen GP 30 16 60 32*
Out-patient appointment 20 11 20 11
Contact with social 
services
4 2 4 2
Employment/education 
services
8 4 52 26*
Social welfare services 40 19 45 21
Housing/homeless 
services
15 8 23 12
* McNemar test revealed statistically significant changes
Differences Between Those Interviewed 
at 1-year and Those ‘Lost’ to Follow-up
Given that almost one-third of the cohort (32%, n=26) did not 
complete the 1-year follow-up interview, analysis was undertaken 
to determine whether there were any differences between those 
interviewed at 1-year and those ‘lost’ to follow-up at treatment 
intake, which may bias the results in the current document.
Table 9 shows the difference (at treatment intake) in key 
variables between the two groups. Although not statistically 
significant participants interviewed at 1-year were more likely to 
be male, to be on social welfare, to have used heroin, cocaine 
and alcohol in the preceding 90 days, and to have injected a 
drug in the 90 days prior to treatment intake.
Analysis revealed that those lost to follow-up used cocaine on 
significantly more days (prior to treatment intake) than individuals 
interviewed at 1-year.
The intake characteristics and problems of participants 
interviewed at 1-year and those ‘lost’ to follow-up were compared 
using a logistic regression of key variables (age, gender, frequency 
of heroin use, quantity of heroin used, frequency of cocaine 
use, number of drugs used, number of days injecting drug use, 
frequency of alcohol use, previous treatment for drug/alcohol 
use, treatment setting). The results show that the samples did not 
differ significantly.
Table 9 Comparison of participant characteristics 
at treatment intake between those ‘lost’ to 1-year 
follow-up and those interviewed
‘Lost’ Interviewed
(n=26) (n=56)
Gender (% male) 85 91
Mean age (yrs) 26.7 27.6
Age left school (yrs) 15.6 15.3
On social welfare (%) 65 71
Treatment setting 
 Inpatient (%) 85 86
 Outpatient (%) 15 14
Time on waiting list (wks) 4.6 5.2
Rated treatment as very  
important (%)
92 96
Used heroin last 90 days (%) 42 65
Mean days used heroin 22.0 27.4
Used cocaine last 90 days (%) 42 46
Mean days used cocaine 12.5 9.9‡
Used alcohol last 90 days (%) 44 60
Mean days used alcohol 17.9 17.9
 Injected last 90 days (%) 27 30
‡ Paired t-test statistically significant

Authors: Dr Gemma Cox, Dr Catherine Comiskey and Paul Kelly
pantone 138
pantone 527
February 2007Findings 3 : Summary of 1-year outcomes: Abstinence Modality
Conclusion
ROSIE is the first national study to have examined 1-year treatment outcomes for opiate users. The findings presented 
in this document demonstrate that participation in an abstinence-based treatment programme is followed by positive 
outcomes in drug use, involvement in crime, and physical and mental health symptoms. These improvements are in line 
with those observed in similar international studies.
The percentage of ROSIE participants followed-up and interviewed 1-year after treatment intake is comparable with the 
international literature. A total of 68% of the ROSIE abstinence cohort completed a 1-year interview. The UK NTORS 
follow-up rate was similar; Gossop et al (1999)1 report a 1-year follow-up interview rate of 67.4% for individuals 
recruited within residential programmes. The Australia ATOS study, report a follow-up rate of 78% within the cohort of 
participants recruited from residential rehabilitation (Teesson et al, 2006)2. However it should be noted that unlike the 
ROSIE study and the NTORS study, participants within ATOS were paid for their treatment intake interview which may 
have influenced the study retention rate. 
In terms of treatment involvement at 1-year, the ROSIE cohort compared very favourably with NTORS and ATOS. At 1-year 
64% of the ROSIE participants were in some form of treatment. Within NTORS residential rehabilitation cohort, Gossop 
et al (1999) report that 60% of participants received some form of treatment during the year and within ATOS, 49% of 
their residential rehabilitation cohort were in some form of treatment at 1-year (Teesson et al, 2006).
The ROSIE participants reported substantial reductions in the use of cocaine and methadone (non-prescribed) in terms 
of the numbers reporting use, the frequency of use and the quantities consumed. In addition, the numbers reporting 
the use of all other target drugs except cannabis reduced significantly. Fifty-eight per cent of the ROSIE participants had 
not used heroin within the 90 days prior to 1-year interview, this compares very favourably with NTORS where a heroin 
abstinence rate of 50.5% in the previous 90 days was observed. Within the Australian study the authors reported that 
63% of the cohort had been abstinent from heroin within the last month. As in other studies (Gossop et al, 2000)3 
disappointing improvements were observed in study participants’ drinking behaviour. Although there was a significant 
reduction in the percentage of ROSIE participants who reported drinking in the 90 days prior to 1-year follow-up interview 
as compared with treatment intake interview, reductions in frequency and average daily quantity of alcohol used were 
non-significant.
The ROSIE cohort reported significant reductions in selling/supplying drugs and in acquisitive crime, comparable with 
international literature. The proportion of ROSIE participants selling/supplying drugs in the 90 days prior to interview 
reduced from 35% at treatment intake to 9% at 1-year follow-up. Within NTORS a similar proportion (33%) reported 
selling drugs at treatment intake but this only reduced to 17% at 1-year follow-up (Gossop et al, 1999). The proportion 
of ROSIE participants who reported involvement in acquisitive crime in the 90 days prior to interview reduced by 22 
percentage points from 35% at treatment intake to 13% at 1-year follow-up. A similar reduction was reported by Gossop 
et al (1999); 51% were involved in acquisitive crime at treatment intake this reduced by 25 percentage points to 26% at 
1-year follow-up.
In conclusion, results on outcomes at 1-year for individuals recruited in the abstinence modality compare very favourably 
with other international outcome studies. However, further research is required to assess if improvements observed at 
1-year are sustainable in the long-term. The forthcoming results from the ROSIE 3-year follow-up will provide stronger 
evidence on the effectiveness of abstinence-based treatment programmes and will enable policy makers and planners to 
make more informed decisions.
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